Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Perioperative laboratory monitoring in congenital haemophilia patients with inhibitors: a systematic literature review.

Hart DP, Hay CRM, Liesner R, Tobaruela G, Du-Mont B, Makris M.

Blood Coagul Fibrinolysis. 2019 Aug 7. doi: 10.1097/MBC.0000000000000840. [Epub ahead of print]

PMID:
31397688
2.

Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program.

Lissitchkov T, Klukowska A, Pasi J, Kessler CM, Klamroth R, Liesner RJ, Belyanskaya L, Walter O, Knaub S, Bichler J, Jansen M, Oldenburg J.

Ther Adv Hematol. 2019 Jun 26;10:2040620719858471. doi: 10.1177/2040620719858471. eCollection 2019. Review.

3.

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.

Carcao M, Escuriola-Ettingshausen C, Santagostino E, Oldenburg J, Liesner R, Nolan B, Bátorová A, Haya S, Young G; Future of Immunotolerance Treatment Group.

Haemophilia. 2019 Jul;25(4):676-684. doi: 10.1111/hae.13762. Epub 2019 Apr 29.

PMID:
31033112
4.

Spinal dorsal rhizotomy plus concurrent left and right gastrocnemii releases in a 7-year-old child with haemophilia A and spastic cerebral palsy.

Bladen M, Main E, Chugh D, Liesner R.

Haemophilia. 2019 May;25(3):e191-e195. doi: 10.1111/hae.13715. Epub 2019 Mar 13. No abstract available.

PMID:
30866113
5.

Characterization and treatment of congenital thrombotic thrombocytopenic purpura.

Alwan F, Vendramin C, Liesner R, Clark A, Lester W, Dutt T, Thomas W, Gooding R, Biss T, Watson HG, Cooper N, Rayment R, Cranfield T, van Veen JJ, Hill QA, Davis S, Motwani J, Bhatnagar N, Priddee N, David M, Crowley MP, Alamelu J, Lyall H, Westwood JP, Thomas M, Scully M.

Blood. 2019 Apr 11;133(15):1644-1651. doi: 10.1182/blood-2018-11-884700. Epub 2019 Feb 15.

PMID:
30770395
6.

Genotype analysis and identification of novel mutations in a multicentre cohort of patients with hereditary factor X deficiency.

Mitchell M, Gattens M, Kavakli K, Liesner R, Payne J, Norton M, Austin S.

Blood Coagul Fibrinolysis. 2019 Jan;30(1):34-41. doi: 10.1097/MBC.0000000000000787.

PMID:
30507709
7.

Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.

Preijers T, Hazendonk HCAM, Liesner R, Chowdary P, Driessens MHE, Hart D, Keeling D, Laros-van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Collins PW, Cnossen MH, Mathôt RAA; OPTI‐CLOT study group.

J Thromb Haemost. 2018 Nov;16(11):2196-2207. doi: 10.1111/jth.14292. Epub 2018 Oct 28.

PMID:
30394056
8.

Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee.

Collins PW, Liesner R, Makris M, Talks K, Chowdary P, Chalmers E, Hall G, Riddell A, Percy CL, Hay CR, Hart DP.

Haemophilia. 2018 May;24(3):344-347. doi: 10.1111/hae.13495.

PMID:
30070072
9.
10.

Perioperative replacement therapy in haemophilia B: An appeal to "B" more precise.

Hazendonk HCAM, Preijers T, Liesner R, Chowdary P, Hart D, Keeling D, Driessens MHE, Laros-van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Mathôt RAA, Collins PW, Cnossen MH.

Haemophilia. 2018 Jul;24(4):611-618. doi: 10.1111/hae.13469. Epub 2018 Apr 29.

PMID:
29707861
11.

Long-term tolerability, immunogenicity and efficacy of Nuwiq® (human-cl rhFVIII) in children with severe haemophilia A.

Klukowska A, Szczepański T, Vdovin V, Knaub S, Bichler J, Jansen M, Dzhunova I, Liesner RJ.

Haemophilia. 2018 Jul;24(4):595-603. doi: 10.1111/hae.13460. Epub 2018 Mar 26.

PMID:
29582516
12.

Vaccinations are not associated with inhibitor development in boys with severe haemophilia A.

Platokouki H, Fischer K, Gouw SC, Rafowicz A, Carcao M, Kenet G, Liesner R, Kurnik K, Rivard GE, van den Berg HM.

Haemophilia. 2018 Mar;24(2):283-290. doi: 10.1111/hae.13387. Epub 2017 Dec 15.

PMID:
29243367
13.

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.

Mancuso ME, Fischer K, Santagostino E, Oldenburg J, Platokouki H, Königs C, Escuriola-Ettingshausen C, Rivard GE, Cid AR, Carcao M, Ljung R, Petrini P, Altisent C, Kenet G, Liesner R, Kurnik K, Auerswald G, Chambost H, Mäkipernaa A, Molinari AC, Williams M, van den Berg HM; European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group.

Thromb Haemost. 2017 Dec;117(12):2274-2282. doi: 10.1160/TH17-01-0059. Epub 2017 Dec 6.

PMID:
29212115
14.

Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.

Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ.

Haemophilia. 2018 Mar;24(2):211-220. doi: 10.1111/hae.13320. Epub 2017 Aug 16.

PMID:
28815880
15.

The haemtrack home therapy reporting system: Design, implementation, strengths and weaknesses: A report from UK Haemophilia Centre Doctors Organisation.

Hay CRM, Xiang H, Scott M, Collins PW, Liesner R, Dolan G, Hollingsworth R.

Haemophilia. 2017 Sep;23(5):728-735. doi: 10.1111/hae.13287. Epub 2017 Aug 14.

PMID:
28806858
16.

Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment.

Andersson NG, Auerswald G, Barnes C, Carcao M, Dunn AL, Fijnvandraat K, Hoffmann M, Kavakli K, Kenet G, Kobelt R, Kurnik K, Liesner R, Mäkipernaa A, Manco-Johnson MJ, Mancuso ME, Molinari AC, Nolan B, Perez Garrido R, Petrini P, Platokouki HE, Shapiro AD, Wu R, Ljung R.

Br J Haematol. 2017 Oct;179(2):298-307. doi: 10.1111/bjh.14844. Epub 2017 Jul 12.

PMID:
28699675
17.

First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties.

Collins P, Chalmers E, Alamelu J, Hay C, Liesner R, Makris M, Mathias M, Payne J, Rangarajan S, Richards M, Talks K, Tunstall O, Williams M, Hart DP.

Haemophilia. 2017 Sep;23(5):654-659. doi: 10.1111/hae.13264. Epub 2017 Jun 2. No abstract available.

PMID:
28574205
18.

Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.

Mullins ES, Stasyshyn O, Alvarez-Román MT, Osman D, Liesner R, Engl W, Sharkhawy M, Abbuehl BE.

Haemophilia. 2017 Mar;23(2):238-246. doi: 10.1111/hae.13119. Epub 2016 Nov 27.

PMID:
27891721
19.

Patterns of bruising in preschool children with inherited bleeding disorders: a longitudinal study.

Collins PW, Hamilton M, Dunstan FD, Maguire S, Nuttall DE, Liesner R, Thomas AE, Hanley J, Chalmers E, Blanchette V, Kemp AM.

Arch Dis Child. 2017 Dec;102(12):1110-1117. doi: 10.1136/archdischild-2015-310196. Epub 2016 Jul 22.

20.

The incidence, risk and functional outcomes of intracranial haemorrhage in children with inherited bleeding disorders at one haemophilia center.

Bladen M, Main E, Khair K, Hubert N, Koutoumanou E, Liesner R.

Haemophilia. 2016 Jul;22(4):556-63. doi: 10.1111/hae.12938. Epub 2016 May 19.

PMID:
27194592
21.

A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders.

Simeoni I, Stephens JC, Hu F, Deevi SV, Megy K, Bariana TK, Lentaigne C, Schulman S, Sivapalaratnam S, Vries MJ, Westbury SK, Greene D, Papadia S, Alessi MC, Attwood AP, Ballmaier M, Baynam G, Bermejo E, Bertoli M, Bray PF, Bury L, Cattaneo M, Collins P, Daugherty LC, Favier R, French DL, Furie B, Gattens M, Germeshausen M, Ghevaert C, Goodeve AC, Guerrero JA, Hampshire DJ, Hart DP, Heemskerk JW, Henskens YM, Hill M, Hogg N, Jolley JD, Kahr WH, Kelly AM, Kerr R, Kostadima M, Kunishima S, Lambert MP, Liesner R, López JA, Mapeta RP, Mathias M, Millar CM, Nathwani A, Neerman-Arbez M, Nurden AT, Nurden P, Othman M, Peerlinck K, Perry DJ, Poudel P, Reitsma P, Rondina MT, Smethurst PA, Stevenson W, Szkotak A, Tuna S, van Geet C, Whitehorn D, Wilcox DA, Zhang B, Revel-Vilk S, Gresele P, Bellissimo DB, Penkett CJ, Laffan MA, Mumford AD, Rendon A, Gomez K, Freson K, Ouwehand WH, Turro E.

Blood. 2016 Jun 9;127(23):2791-803. doi: 10.1182/blood-2015-12-688267. Epub 2016 Apr 15.

22.

The ophthalmic presentation of Hermansky-Pudlak syndrome 6.

Hull S, Arno G, Holder GE, Plagnol V, Gomez K, Liesner R, Webster AR, Moore AT.

Br J Ophthalmol. 2016 Nov;100(11):1521-1524. doi: 10.1136/bjophthalmol-2015-308067. Epub 2016 Jan 28.

PMID:
26823395
23.

Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq® ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics.

Klukowska A, Szczepański T, Vdovin V, Knaub S, Jansen M, Liesner R.

Haemophilia. 2016 Mar;22(2):232-239. doi: 10.1111/hae.12797. Epub 2015 Sep 14.

PMID:
26370328
24.

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.

Nolan B, Mahlangu J, Perry D, Young G, Liesner R, Konkle B, Rangarajan S, Brown S, Hanabusa H, Pasi KJ, Pabinger I, Jackson S, Cristiano LM, Li X, Pierce GF, Allen G.

Haemophilia. 2016 Jan;22(1):72-80. doi: 10.1111/hae.12766. Epub 2015 Jul 27.

PMID:
26218032
25.

Using routine Haemophilia Joint Health Score for international comparisons of haemophilia outcome: standardization is needed.

Nijdam A, Bladen M, Hubert N, Pettersson M, Bartels B, van der Net J, Liesner R, Petrini P, Kurnik K, Fischer K.

Haemophilia. 2016 Jan;22(1):142-7. doi: 10.1111/hae.12755. Epub 2015 Jul 14.

PMID:
26179669
26.

Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders.

Westbury SK, Turro E, Greene D, Lentaigne C, Kelly AM, Bariana TK, Simeoni I, Pillois X, Attwood A, Austin S, Jansen SB, Bakchoul T, Crisp-Hihn A, Erber WN, Favier R, Foad N, Gattens M, Jolley JD, Liesner R, Meacham S, Millar CM, Nurden AT, Peerlinck K, Perry DJ, Poudel P, Schulman S, Schulze H, Stephens JC, Furie B, Robinson PN, van Geet C, Rendon A, Gomez K, Laffan MA, Lambert MP, Nurden P, Ouwehand WH, Richardson S, Mumford AD, Freson K; BRIDGE-BPD Consortium.

Genome Med. 2015 Apr 9;7(1):36. doi: 10.1186/s13073-015-0151-5. eCollection 2015.

27.

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.

Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S, Gambino G, Cristiano LM, Pierce GF, Allen G.

J Thromb Haemost. 2015 Jun;13(6):967-77. doi: 10.1111/jth.12911. Epub 2015 Apr 23.

28.

How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access.

Nijdam A, Kurnik K, Liesner R, Ljung R, Nolan B, Petrini P, Fischer K; PedNet study group.

Haemophilia. 2015 Jul;21(4):444-50. doi: 10.1111/hae.12613. Epub 2015 Jan 13.

PMID:
25582494
29.

The value of the white precursor cell channel (WPC) on the Sysmex XN-1000 analyser in a specialist paediatric hospital.

Jones AS, Tailor H, Liesner R, Machin SJ, Briggs CJ.

J Clin Pathol. 2015 Feb;68(2):161-5. doi: 10.1136/jclinpath-2014-202640. Epub 2014 Nov 25.

PMID:
25425659
30.

A national survey of immunosuppression strategies for acquired haemophilia A.

Batty P, Palmer B, Chalmers E, Hay CR, Liesner R, Rangarajan S, Talks K, Williams M, Collins P, Hart DP.

Haemophilia. 2015 Jan;21(1):e73-6. doi: 10.1111/hae.12547. Epub 2014 Nov 24. No abstract available.

PMID:
25422109
31.

The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison.

Hay CR, Palmer BP, Chalmers EA, Hart DP, Liesner R, Rangarajan S, Talks K, Williams M, Collins PW.

Haemophilia. 2015 Mar;21(2):219-26. doi: 10.1111/hae.12563. Epub 2014 Nov 7.

PMID:
25382829
32.

Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.

Collins PW, Palmer BP, Chalmers EA, Hart DP, Liesner R, Rangarajan S, Talks K, Williams M, Hay CR; UK Haemophilia Centre Doctors’ Organization.

Blood. 2014 Nov 27;124(23):3389-97. doi: 10.1182/blood-2014-07-580498. Epub 2014 Oct 22.

33.

Wilate use in 47 children with von Willebrand disease: the North London paediatric haemophilia network experience.

Khair K, Batty P, Riat R, Bowles L, Burgess C, Chen YH, Hart D, Platton S, Pasi J, Liesner R.

Haemophilia. 2015 Jan;21(1):e44-50. doi: 10.1111/hae.12497. Epub 2014 Aug 12.

PMID:
25112927
34.

Similar bleeding phenotype in young children with haemophilia A or B: a cohort study.

Clausen N, Petrini P, Claeyssens-Donadel S, Gouw SC, Liesner R; PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group.

Haemophilia. 2014 Nov;20(6):747-55. doi: 10.1111/hae.12470. Epub 2014 Jun 3.

PMID:
24893572
35.

Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry.

Fischer K, Ljung R, Platokouki H, Liesner R, Claeyssens S, Smink E, van den Berg HM.

Haemophilia. 2014 Jul;20(4):e280-6. doi: 10.1111/hae.12448. Epub 2014 May 2.

PMID:
24784937
36.

Washing red cells after leucodepletion does not decrease human leukocyte antigen sensitization risk in patients with chronic kidney disease.

Aston A, Cardigan R, Bashir S, Proffitt S, New H, Brown C, Liesner R, Hennem S, Nulty H, Shaw O, Vaughan R, Kim JJ, Rees L.

Pediatr Nephrol. 2014 Oct;29(10):2005-11. doi: 10.1007/s00467-014-2823-6. Epub 2014 Apr 29.

PMID:
24777534
37.

The first recombinant FVIII produced in human cells--an update on its clinical development programme.

Valentino LA, Negrier C, Kohla G, Tiede A, Liesner R, Hart D, Knaub S.

Haemophilia. 2014 Jan;20 Suppl 1:1-9. doi: 10.1111/hae.12322. Review.

PMID:
24330348
38.

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.

Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, Cnossen MH, Dors N, Escuriola-Ettingshausen C, Hamulyak K, Hart DP, Hay CR, Haya S, van Heerde WL, Hermans C, Holmström M, Jimenez-Yuste V, Keenan RD, Klamroth R, Laros-van Gorkom BA, Leebeek FW, Liesner R, Mäkipernaa A, Male C, Mauser-Bunschoten E, Mazzucconi MG, McRae S, Meijer K, Mitchell M, Morfini M, Nijziel M, Oldenburg J, Peerlinck K, Petrini P, Platokouki H, Reitter-Pfoertner SE, Santagostino E, Schinco P, Smiers FJ, Siegmund B, Tagliaferri A, Yee TT, Kamphuisen PW, van der Bom JG, Fijnvandraat K; INSIGHT Study Group.

Blood. 2013 Sep 12;122(11):1954-62. doi: 10.1182/blood-2013-02-483263. Epub 2013 Aug 7. Erratum in: Blood. 2014 May 8;123(19):3056.

PMID:
23926300
39.

Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO.

W Collins P, Chalmers E, Hart D, Jennings I, Liesner R, Rangarajan S, Talks K, Williams M, R M Hay C; United Kingdom Haemophilia Centre Doctors' Organization.

Br J Haematol. 2013 Sep;162(6):758-73. doi: 10.1111/bjh.12463. Epub 2013 Jul 25. No abstract available.

PMID:
23889317
40.

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.

Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, Chambost H, Kurnik K, Liesner R, Petrini P, Platokouki H, Altisent C, Oldenburg J, Nolan B, Garrido RP, Mancuso ME, Rafowicz A, Williams M, Clausen N, Middelburg RA, Ljung R, van der Bom JG; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group.

Blood. 2013 May 16;121(20):4046-55. doi: 10.1182/blood-2012-09-457036. Epub 2013 Apr 3.

PMID:
23553768
41.

Factors affecting the Haemophilia Joint Health Score in children with severe haemophilia.

Bladen M, Main E, Hubert N, Koutoumanou E, Liesner R, Khair K.

Haemophilia. 2013 Jul;19(4):626-31. doi: 10.1111/hae.12108. Epub 2013 Mar 28.

PMID:
23534671
42.

Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies.

Mackie I, Langley K, Chitolie A, Liesner R, Scully M, Machin S, Peyvandi F.

Thromb Haemost. 2013 Mar;109(3):488-96. doi: 10.1160/TH12-08-0565. Epub 2013 Jan 10.

PMID:
23306535
43.

Management of surgical procedures in children with severe FV deficiency: experience of 13 surgeries.

Mathias M, Tunstall O, Khair K, Liesner R.

Haemophilia. 2013 Mar;19(2):256-8. doi: 10.1111/hae.12053. Epub 2012 Nov 23.

PMID:
23173600
44.

Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.

Collins PW, Chalmers E, Hart DP, Liesner R, Rangarajan S, Talks K, Williams M, Hay CR; UK Haemophilia Centre Doctors.

Br J Haematol. 2013 Jan;160(2):153-70. doi: 10.1111/bjh.12091. Epub 2012 Nov 15. No abstract available.

PMID:
23157203
45.

A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom.

Camilleri RS, Scully M, Thomas M, Mackie IJ, Liesner R, Chen WJ, Manns K, Machin SJ.

J Thromb Haemost. 2012 Sep;10(9):1792-801. doi: 10.1111/j.1538-7836.2012.04852.x.

46.

Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.

Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ; British Committee for Standards in Haematology.

Br J Haematol. 2012 Aug;158(3):323-35. doi: 10.1111/j.1365-2141.2012.09167.x. Epub 2012 May 25. No abstract available.

PMID:
22624596
47.

Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura.

Lotta LA, Wu HM, Mackie IJ, Noris M, Veyradier A, Scully MA, Remuzzi G, Coppo P, Liesner R, Donadelli R, Loirat C, Gibbs RA, Horne A, Yang S, Garagiola I, Musallam KM, Peyvandi F.

Blood. 2012 Jul 12;120(2):440-8. doi: 10.1182/blood-2012-01-403113. Epub 2012 Apr 23.

48.

Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A.

Auerswald G, Thompson AA, Recht M, Brown D, Liesner R, Guzmán-Becerra N, Dyck-Jones J, Ewenstein B, Abbuehl B.

Thromb Haemost. 2012 Jun;107(6):1072-82. doi: 10.1160/TH11-09-0642. Epub 2012 Apr 4.

49.

Guidelines for the laboratory investigation of heritable disorders of platelet function.

Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, Machin S; British Committee for Standards in Haematology.

Br J Haematol. 2011 Oct;155(1):30-44. doi: 10.1111/j.1365-2141.2011.08793.x. Epub 2011 Jul 26.

PMID:
21790527
50.

p.Tyr365Cys change in factor VIII: haemophilia A, but not as we know it.

Bowyer AE, Goodeve A, Liesner R, Mumford AD, Kitchen S, Makris M.

Br J Haematol. 2011 Sep;154(5):618-25. doi: 10.1111/j.1365-2141.2011.08688.x. Epub 2011 Jul 14.

PMID:
21751985

Supplemental Content

Loading ...
Support Center